adagrasib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: GTPase KRas.
- Target
- GTPase KRas
- Mechanism
- GTPase KRas inhibitor
pharma · Breast Cancer · NSCLC, synchronous oligo-metastatic
Impact Therapeutics
Partner Therapeutics Limited
Impact Therapeutics drug portfolio — 26 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1004, 10th Floor, Lodha Supremus Saki Vihar Road, Powai, Mumbai-400072, Maharashtra 400072, IN, Lexington HQ
2010 Founded
8 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 1004, 10th Floor, Lodha Supremus Saki Vihar Road, Powai, Mumbai-400072, Maharashtra 400072, IN, Lexington
- Founded
- 2010
- Employees
- 8
- Programs
- 12
- Drugs
- 26
- Patents
- 0
Impact Therapeutics pipeline
Portfolio lens on 26 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Impact Therapeutics drug portfolio — 26 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
Development asset linked to Impact Therapeutics in public FDA and regional records.
-
Development asset linked to Impact Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
- Target
- Adrenergic receptor alpha-1
- Mechanism
- Adrenergic receptor beta antagonist
-
cemiplimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Impact Therapeutics's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Impact Therapeutics in public FDA and regional records.
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
palbociclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: CDK6/cyclin D1.
- Target
- CDK6/cyclin D1
- Mechanism
- Cyclin-dependent kinase 4/cyclin D1 inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Impact Therapeutics in public FDA and regional records.
-
Development asset linked to Impact Therapeutics in public FDA and regional records.
-
Development asset linked to Impact Therapeutics in public FDA and regional records.
-
Development asset linked to Impact Therapeutics in public FDA and regional records.
-
tarlatamab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Impact Therapeutics's portfolio. Molecular target: Delta-like protein 3.
- Target
- Delta-like protein 3
- Mechanism
- Delta-like protein 3 binding agent
-
Development asset linked to Impact Therapeutics in public FDA and regional records.
-
tremelimumab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Impact Therapeutics's portfolio. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor